CLAIMS

1. Use of a PIC1 peptide in the manufacture of a medicament for the treatment of acute lung injury in a subject, wherein the PIC1 peptide comprises the sequence of IALILEPICCQERAA-dPEG24 (SEQ ID NO: 19), and
wherein the subject has not received an allogeneic blood product transfusion within six hours of receiving the PIC1 peptide.

2. Use of a PIC1 peptide in the manufacture of a medicament for the treatment of acute respiratory distress syndrome in a subject, wherein the PIC1 peptide comprises the sequence of IALILEPICCQERAA-dPEG24 (SEQ ID NO: 19), and
wherein the subject has not received an allogeneic blood product transfusion within six hours of receiving the PIC1 peptide.

3. The use of claim 1 or claim 2, wherein the PIC1 peptide is effective to inhibit inflammation in the subject.

4. The use of any one of claims 1 to 3, wherein the PIC1 peptide is effective to inhibit inflammatory tissue damage in the subject.

5. The use of any one of claims 1 to 4, wherein the PIC1 peptide is effective to preserve normal lung architecture in the subject.

6. The use of any one of claims 1 to 5, wherein the PIC1 peptide is effective to inhibit one or more of lung damage, neutrophil invasion into lung tissue, and MPO activity in lung tissue.

7. The use of any one of claims 1 to 6, wherein the PIC1 peptide is effective to inhibit immune complex activation of the complement system in the subject.

8. The use of any one of claims 1 to 7, wherein the PIC1 peptide is effective to inhibit NET formation in the subject.

9. The use of claim 8, wherein the NET formation is stimulated by at least one of a bacterium, a fungus, a parasite or a virus.

10. The use of claim 9, wherein the NET formation is stimulated by a virus.

11. The use of claim 10, wherein the PIC1 peptide is to be administered at a dose of from 5 to 100 mg/kg body weight of the subject.

12. The use of any one of claims 1 to 11, wherein the PIC1 peptide is formulated for intravenous administration.